Oralin Buccal Insulin May Face Easier Regulatory Path Than Inhaled Insulins, Generex Consultant Predicts
This article was originally published in The Pink Sheet Daily
Executive Summary
Oralin exposes only the oral cavity to insulin, Generex consultant Fleming says. Generex will pursue international approvals first with a more limited data package than FDA requires. Phase IIb trials have started in type 2 diabetes.
You may also be interested in...
Lilly/Alkermes Inhaled Insulin To Enter Late-Stage Development
The companies are finalizing plans for Phase II and Phase III trials following successful Phase II study in type 1 diabetes and completion of manufacturing scale-up and inhaler device development. The partnership is Lilly’s third stab at non-injectable insulin development.
Lilly/Alkermes Inhaled Insulin To Enter Late-Stage Development
The companies are finalizing plans for Phase II and Phase III trials following successful Phase II study in type 1 diabetes and completion of manufacturing scale-up and inhaler device development. The partnership is Lilly’s third stab at non-injectable insulin development.
Aradigm/Novo Nordisk Inhaled Insulin Manufacturing Issues Appear Resolved
Concerns over cosmetic blemishes on liquid insulin strips had delayed initiation of additional Phase III trials. Aradigm sees increased interest in its AERx pulmonary delivery system in the wake of Pfizer’s recent optimism about Exubera.